[go: up one dir, main page]

EP0644940A1 - PROCEDE ENZYMATIQUE POUR LA PRODUCTION D'ACIDE $i(S)-6-METHOXY-ALPHA-METHYLE-2 NAPHTALENACETIQUE - Google Patents

PROCEDE ENZYMATIQUE POUR LA PRODUCTION D'ACIDE $i(S)-6-METHOXY-ALPHA-METHYLE-2 NAPHTALENACETIQUE

Info

Publication number
EP0644940A1
EP0644940A1 EP93911192A EP93911192A EP0644940A1 EP 0644940 A1 EP0644940 A1 EP 0644940A1 EP 93911192 A EP93911192 A EP 93911192A EP 93911192 A EP93911192 A EP 93911192A EP 0644940 A1 EP0644940 A1 EP 0644940A1
Authority
EP
European Patent Office
Prior art keywords
sequence
naproxen
ester
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93911192A
Other languages
German (de)
English (en)
Inventor
Hardy W. Chan
Richard Freedman
Felix H. Salazar
Steven R. Beck
Robert O. Cain
Christopher R. Roberts
Roger C. Synder
Patricia Phelps
Donald L. Heefner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex Pharmaceuticals International Ltd
Original Assignee
Syntex Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Pharmaceuticals International Ltd filed Critical Syntex Pharmaceuticals International Ltd
Publication of EP0644940A1 publication Critical patent/EP0644940A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four

Definitions

  • This invention relates to the preparation of (S)- ⁇ -methoxy- ⁇ -methyl- 2-naphthaleneacetic acid by the enanti ⁇ elective hydrolysis of racemic esters using microorganisms and enzymes derived therefrom.
  • Naproxen is the USAN and INN nonproprietary name for (S)- 6-methoxy- -methyl-2-napththaleneacetic acid.
  • naproxen and A,S-naproxen mean a mixture of the A- and S-enantiomers of 6-methoxy- ⁇ -methyl-2-napththaleneacetic acid, especially a racemic mixture; and "A-naproxen” and “S-naproxen” mean the two enantiomers individually.
  • S-naproxen used in this application corresponds to the USAN/INN name "naproxen”.
  • naproxen is an acid
  • the terms "naproxen”, “A,S-naproxen”, “A-naproxen”, and “S-naproxen” include not only the acid form of the compound, but also the anion form and pharmaceutically acceptable salts of the acid form, unless the context requires otherwise.
  • EP 0 153 474 describes the process of preparing S-naproxen from R,S- naproxen ester using microbial enzymes, but requires a two step hydrolysis proces ⁇ .
  • the A, -naproxen ester is first enantioselectively hydrolyzed to S-naproxen ester and A-naproxen with a microbial esterase, preferably from Aspergillus, and the A-naproxen separated.
  • the S-naproxen ester is then nonselectively hydrolyzed by esterase from hog liver or Pleurotus ostreatus to form the desired S-naproxen.
  • U.S. Patent No. 4,762,793 describes an enzymatic process in which enantioselective hydrolysis of A,S- ⁇ -arylalkanoic esters is carried out using a lipase enzyme isolated from Candida cylindracea. When used in the production of S-naproxen, this process took over two days at 32°C to convert 40% of A,S-naproxen ester to S-naproxen. Moreover, the enzyme loses about 80% of its activity over a 96 hour reaction period. (See also, EP 0 195 717).
  • EP 0205 215 describes the process of preparing
  • EP 0 227 078 describes the process of preparing
  • S- -methylareneacetic acids from A,S-naproxen esters using extracellular lipases of microbial origin preferably Candida cylindracea.
  • Candida cylindracea lipase required several days to convert 41% of methyl A,S-naproxen ester into S-naproxen. This rate of conversion is too slow to be suitable for a high yield, low cost industrial process.
  • EP 0 328 125 describes a process for the enzymatically catalyzed enantioselective transesterification of racemic alcohols, such as (A,S)-6- methoxy- ⁇ -methyl-2-naphthaleneethanol, with an ester such as ethyl acetate, methyl acetate or methyl propionate, to afford the ester of the S-alcohol.
  • racemic alcohols such as (A,S)-6- methoxy- ⁇ -methyl-2-naphthaleneethanol
  • an ester such as ethyl acetate, methyl acetate or methyl propionate
  • the resulting esters are said to be useful in the preparation of anti-inflammatory agents such as S-naproxen.
  • Preferred enzymes are steapsin and the lipase from Pseudomonas fluorescens.
  • EP 0 330 217 describes a continuous enzymatic process for the preparation of S-naproxen from an alkoxyethyl A, -naproxen ester using a lipase isolated from Candida cylindracea.
  • the enzymatic reaction gave a 37% conversion of A,S-naproxen ester at 35°C after 500 hours. This rate of conversion is too low for a high yield, low cost process.
  • U.S. Patents Nos. 4,886,750 and 5,037,751 describe a process using microorganisms having the esterase ability for enantioselective hydrolysis of A,S-naproxen esters into S-naproxen having at least 60% ee.
  • the patents describe an esterase that has the ability to enantioselectively hydrolyze A,S-naproxen ester into S-naproxen having at least 98.8% ee.
  • the conversion of A,S-naprcxen ester to 5- naproxen is limited to low substrate concentrations.
  • esterases do not act in a biphasic aqueous/organic system or on insoluble A, -naproxen ester.
  • the disclosed e ⁇ terases require a surfactant, such as Tween*, to be active; thereby restricting their use to a process requiring additional equipment and time to remove the surfactant.
  • PCT/NL90/00058 describes the stabilization of esterases used to enantioselectively hydrolyze A,S-naproxen ester to S-naproxen.
  • the enzymes being stabilized are disclosed in U.S. Patents Nos. 4,886,750 and 5,037,751.
  • the described esterase is almost completely inactivated by the S-naproxen formed by the hydrolysis.
  • these stabilizing agents include the preferred agent, formaldehyde
  • these stabilizing agents are known carcinogens that must be removed by extensive processing for the product to be used in humans.
  • the ability to run such a hydrolysis reaction without the need for carcinogenic stabilizing agents is a highly desirable characteristic.
  • the rate of an enzymatic reaction depends on the reaction temperature.
  • An enzyme exhibiting thermal stability permits running the reaction at a higher temperature which accelerates the rate, which in turn increases the production throughput.
  • high temperature also drives the solid ester substrate towards its molten form, rendering the control of solid particle size less critical. It is, therefore, desirable to conduct the reaction at the highest temperature that can be tolerated by the enzyme. To this end, it is desirable to develop an enzyme that exhibits high thermal stability.
  • a process for the production of S-naproxen comprising the enantioselective hydrolysis of A,S-naproxen ester by an ester hydrolase selected from ester hydrolases produced by a microorganism of the group Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis, Eupenicillium baarnenses, Graphium sp . , Heterocephalum aurantiacu , Pencilliu roguefortii and Zopfiella latipes is described.
  • a coding region of a gene encoding for an ester hydrolase capable of enantioselective hydrolysis of an A,S-naproxen ester which region comprise the nucleotide sequence as set forth in Sequence I.D. No. 2, Sequence I.D. No. 5, Sequence I.D. No. 8, Sequence I.D. No. 11 or Sequence I.D. No. 14, or a sequence that hybridizes thereto is described.
  • an ester hydrolase capable of the enantioselective hydrolysis of an A,S-naproxen ester to S- naproxen wherein said ester hydrolase hydrolyzes the reaction of A,S- naproxen ester at a temperature range from about 35°C to about 65°C is described.
  • ester hydrolase capable of the enantioselective hydrolysis of ethyl A,S-naproxen ester to S-naproxen, which ester hydrolase comprises an amino acid sequence as set forth in Sequence I.D. No. 3, Sequence I.D. No. 6, Sequence I.D. No. 9, Sequence I.D. No. 12 or Sequence I.D. No. 15.
  • ester hydrolase capable of the enantioselective hydrolysis of n-propyl A,S-naproxen ester to S-naproxen, which ester hydrolase comprises an amino acid sequence a ⁇ set forth in Sequence I.D. No. 3, Sequence I.D. No. 6, Sequence I.D. No. 9, Sequence I.D. No. 12 or Sequence I.D. No. 15.
  • Figure 1(a) is a diagram illustrating cDNA synthesis for the ester hydrolase gene in E. coli.
  • Figure 1(b) shows the construction of the yeast expression plasmid for the ester hydrolase gene.
  • Figure 2 shows the degenerate oligonucleotide primers based on the partial amino acid sequences determined for the first 20 amino acids at the N-terminus a ⁇ well as the four internal cyanogen bromide cleaved fragments of the Zopfiella ester hydrolase.
  • Figure 3 shows the nucleotide junction sequences and the inferred amino acid sequences between the Zopfiella cDNA and the plasmid vector.
  • Figure 4 shows the enhanced thermal tolerance of rec 780-mlO over rec 780.
  • Figure 5 is a schematic flowsheet for an immobilized Zopfiella bioreactor system.
  • Seq. I.D. No. 1 fusion protein sequence of the gene for ester hydrolase from Zopfiella rec 511 gene.
  • Seq. I.D. No. 2 nucleotide sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 511 gene, inferred amino acid sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 511 gene.
  • nucleotide sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 780 gene inferred amino acid sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 780 gene.
  • Seq. I.D. No. 7 fusion protein sequence of the gene for ester hydrolase from Zopfiella rec 780-mlO gene.
  • Seq. I.D. No. 8 nucleotide sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 780-mlO gene.
  • Seq. I.D. No. 9 inferred amino acid sequence of the coding region of the gene for ester hydrolase from Zopfiella rec 780-mlO gene.
  • Seq. I.D. No. 10 fusion protein sequence of the gene for ester hydrolase from Zopfiella rec 780-165 gene. Seq. I.D. No.
  • the present invention relates to a process for producing S-naproxen by presenting A, -naproxen ester to the action of an ester hydrolase isolated from a microorganism selected from the group Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis, Eupenicillium baarnenses, Graphium sp. , Heterocephalum aurantiacum, Pencillium roguefortii and Zopfiella latipes to enantioselectively catalyze the hydrolysis of A,S-naproxen ester to S-naproxen.
  • an ester hydrolase isolated from a microorganism selected from the group Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis, Eupenicillium baarnenses, Graphium sp. , Heterocephalum aurantiacum, Pencillium roguefor
  • this invention relates to the screening of a panel of microorganisms in order to identify a microorganism that produces an ester hydrolase of use in the high yield, low cost production of S- naproxen.
  • the gene for the native enzyme is cloned and expressed in a suitable host.
  • the recombinant enzyme is then used in the high yield, low cost production of S-naproxen.
  • Zopfiella latipes hereinafter Zopfiella family of microorganisms was found to produce an ester hydrolase enzyme that met the stringent criteria for commercial production, including yielding S-naproxen having an enantiomeric excess greater than 98%.
  • this invention relates to a high yield, low cost process for the production of S-naproxen.
  • S-naproxen includes the pharmaceutically acceptable salts of S-naproxen, in particular the sodium salt.
  • the invention thus includes those processes wherein the S-naproxen formed by enantioselective hydrolysis is converted to a pharmaceutically acceptable salt and those processes in which it is not.
  • A,S-naproxen ester or “racemic naproxen ester” mean a mixture of the A- and S-enantiomers of varying or equal ratios of an ester of 6-methoxy- ⁇ -methyl-2-naphthaleneacetic acid.
  • A,S-naproxen ester is defined by the following formula: -8-
  • R is alkyl, cycloalkyl, aralkyl or aryl.
  • R is lower alkyl, and more preferably R is ethyl or n-propyl.
  • alkyl refers to both straight and branched chain alkyl groups having total of 1 to 12 carbon atoms, thus including primary, secondary and tertiary alkyl groups.
  • Typical alkyls include, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-amyl, n- hexyl and the like.
  • “Lower alkyl” refers to alkyl groups having 1 to 4 carbon atoms.
  • Typical lower alkyls include, for example, methyl, ethyl, n-propyl and the like.
  • Cycloalkyl refers to cyclic hydrocarbon groups having from 3 to 12 carbon atoms such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • Lower cycloalkyl refers to cycloalkyl groups having 3 to 6 carbon atoms.
  • Aryl refers to a monovalent unsaturated aromatic carbocyclic radical having a single ring (e.g., phenyl) or two condensed rings (e.g., naphthyl).
  • Alkyl refers to an aryl substituted alkyl group, such as, for example, benzyl or phenethyl.
  • alkyl, cycloalkyl, aryl or aralkyl group can be optionally substituted with one or more non-interfering electron-withdrawing substituents, for example, halo, nitro, cyano, phenyl, hydroxy, alkoxy, alkylthio, or -C(0)R' wherein R 1 is lower alkyl, lower cycloalkyl, hydroxy, alkoxy, cycloalkoxy, phenoxy, benzyloxy, NRR 3 (in which R 2 and R 3 are independently H, lower alkyl, lower cycloalkyl, or jointly form a 5- or 6-membered ring together with the nitrogen, the ring optionally including a hetero group selected from O, NH, or N-(lower alkyl)), or -OM wherein M is an alkali metal. -9-
  • non-interfering characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention.
  • Halo refers to iodo, bromo, chloro and fluoro.
  • Alkoxy refers to the group having the formula -OR*, wherein R* is lower alkyl, as defined above. Typical alkoxy groups include, for example, methoxy, ethoxy, t-butoxy and the like.
  • Alkylthio refers to the group having the formula -SR 5 , wherein R 5 is lower alkyl, as defined above. Typical alkylthio groups include, for example, thiomethyl, thioethyl and the like.
  • Cycloalkoxy refers to the group having the formula -OR 6 , wherein R* is lower cycloalkyl, as defined above.
  • Typical cycloalkoxy groups include, for example, cyclopropyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • Alkali metal refers to sodium, potassium, lithium and cesium.
  • the electron-withdrawing substituents are preferably at the a- or ⁇ - position of the R group, to the extent consistent with the stability of the group.
  • Esters in which the R groups contain electron-withdrawing substituents are referred to as activated esters, since they generally hydrolyze more rapidly than those where the R group is not so substituted.
  • alkyl groups are methyl, ethyl, n-propyl, t-butyl, n-hexyl, i-octyl, n-dodecyl, benzyl, 2-chloroethyl,
  • Organic solvents includes solvents such as methanol, ethanol, acetic acid, methylene chloride, chloroform, tetrahydrofuran, dimethoxyethane, dimethylformamide, dimethylsulfoxide, benzene, toluene, carbon tetrachloride and the like.
  • Base refers to bases such as alkali metal hydroxides, alkali metal alkoxides, alkali metal hydrides, alkali metal di(lower alkyl)amines, alkali metal acetates, alkali metal bicarbonates, alkali metal, tri(lower alkyl)amines, and the like, for example, potassium hydroxide, sodium hydroxide, potassium ethoxide, sodium carbonate, sodium salt of diethyl amine, sodium acetate, potassium bicarbonate, and the like.
  • a “resolving agent” is an optical isomer of a chiral a ine base such as ⁇ -methylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, strychnine, brucine, morphine, ot-phenylethylamine, arginine, dehydroabietylamine, 2-amino-l-propanol, amphetamine, gluco ⁇ amine, conessine, anabasine, ephedrine and the like.
  • MeNPR Metal naproxen ester
  • n-Propyl naproxen ester or “n-PrNPR” refers to the compound of Formula I when R is n-propyl.
  • S-p-nitrophenyl ester or "S-PEN” refers to the compound of Formula I when R is p-nitrophenyl.
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick- layer (preparative) chromatography, distillation, or a combination of these procedures.
  • suitable separation and isolation procedures can be had by references to the examples herein. However, other equivalent separation or isolation procedures can, of course, also be used.
  • Recombinant enzyme refers to an ester hydrolase obtained by the cloning of a Zopfiella ester hydrolase gene into a suitable expression system. Whether used in the singular or plural form, “recombinant enzyme” refers to these particularly defined ester hydrolase enzymes, either as a group or individually.
  • the identifier "rec” will be used with the name of the clone, for example, rec 511 refers to the recombinant enzyme from Zopfiella strain 511, and so on.
  • Fusion protein means a fusion protein of the recombinant ester hydrolase having a sequence expressed as a fusion between all or a portion of the sequence for the Zopfiella ester hydrolase and a heterologous protein.
  • regulatory region means the expression control sequence, for example, a promoter and ribosome binding site, necessary for transcription and translation.
  • Stability means the retention of enzymatic activity under defined reaction conditions.
  • High Thermal Stability refers to a temperature of about 10"C above T , where T3$ is defined as the temperature at which one-half of the enzymatic activity of a reference ester hydrolase is lost within one hour.
  • Enantiomeric excess or "ee” means the excess of one enantiomer over the other in a mixture of two enantiomers, such as in the product of an enantioselective reaction; and is typically expressed as a percentage.
  • the %ee of the S-naproxen reaction product refers to the percentage of S-naproxen present minus the percentage of A-naproxen present.
  • Conversion in the enantioselective hydrolysis of A,S-naproxen ester to S-naproxen, means the ratio of S-naproxen produced to the initial A,S-naproxen ester present in a reaction mixture in a given time, and is usually expressed as a percentage.
  • KNPR means the potassium salt of S-naproxen.
  • microorganisms that produce the enzymes of this invention were discovered after selecting over 600 Class 1, i.e. non-pathogenic, microorganisms for screening.
  • the panel of microorganisms screened included 284 fungi, 180 true bacteria, 69 yeasts, 51 filamentous bacteria, 8 algae and 16 unclassified strains.
  • the microorganisms were obtained from the American Type Culture Collection ("ATCC") .
  • ATCC American Type Culture Collection
  • the eleven microorganisms identified appear in Table 1. -12-
  • the dehydrated microorganism is rehydrated and plated out to assess growth and purity of the transported culture. If the microorganism passes a visual inspection for purity, the microorganism is transferred onto slants of a culture medium for initial growth.
  • the microorganisms can be kept on agar slants, in 50% glycerol at -20°C or lyophilized.
  • the culture media used contain an assimilable carbon source, for example glucose, lactate, sucrose and the like; a nitrogen source, for example ammonium sulphate, ammonium nitrate, ammonium chloride and the like; with an agent for an organic nutrient source, for example yeast extract, malt extract, peptone, meat extract and the like; and an inorganic nutrient source, for example phosphate, magnesium, potassium, zinc, iron and other metals in trace amounts.
  • an assimilable carbon source for example glucose, lactate, sucrose and the like
  • a nitrogen source for example ammonium sulphate, ammonium nitrate, ammonium chloride and the like
  • an agent for an organic nutrient source for example yeast extract, malt extract, peptone, meat extract and the like
  • an inorganic nutrient source for example phosphate, magnesium, potassium, zinc, iron and other metals in trace amounts.
  • the preferred medium for a particular microorganism is defined by the slant with the best growth and is used for the liquid culture and assay. Following identification of the preferred medium for liquid culture and assay, a 5% (v/v) inoculum was grown in the defined medium for 24-48 hours, depending on the growth rate of the organism.
  • a preferred growth medium for Absidia griseola is 28, Aspergillus sydowii is 325, Doratomyces stemonitis is 323, Eupenicillium baarnenses is 28, Graphium sp.
  • a temperature between about 10°C and about 40°C and a pH between 4 and 10 is maintained during the growth of the microorganism.
  • the microorganisms are grown at a temperature between about 23°C and about 36°C and at a pH between 5 and 9.
  • the aerobic conditions required during the growth of the microorganisms can be provided according to any of the well-established procedures, provided that the supply of oxygen is sufficient to meet the metabolic requirement of the microorganisms. This is most conveniently achieved by exposing the slant to air.
  • the microorganisms During the hydrolysis of A, -naproxen ester, the microorganisms might be in a growing stage using a culture medium, as described above, or might be preserved in any system (buffer or medium) preventing degradation of enzymes.
  • a culture medium as described above
  • an ordinary culture medium as described above, can be used.
  • the preferred medium for the enantioselective hydrolysis of A,S-naproxen ester with a particular microorganism is the preferred medium used for growth of that microorganism.
  • the microorganisms can be kept in the non-growing stage, for example, by exclusion of the assimilable carbon source or by exclusion of the nitrogen source.
  • a preferred storage medium for Absidia griseola is 336, for Aspergillus sydowii(ATCC #1017) is 312, for Aspergillus sydowii(ATCC #52077) is 325, for Doratomyces stemonitis is 323, for Eupenicillium baarnenses is 325, for Graphium sp.
  • a temperature between about 10°C and about 40°C and a pH between about 4 and 10 is maintained during the assay of the enantioselective hydrolysis of A,S-naproxen ester.
  • the microorganisms are kept at a temperature between about 23°C and about 36°C and at a pH between 5 and 9.
  • the aerobic conditions required during the assay can be provided according to any of the well-established procedures, provided that the supply of oxygen is sufficient to meet the metabolic requirement of the microorganisms. This is most conveniently achieved by supplying oxygen, suitably in the form of air by agitating the reaction liquid.
  • Racemic naproxen ester preferably lower alkyl naproxen ester
  • a sterile organic solvent preferably sterile soybean oil
  • A,S-naproxen ester solution is added to aqueous culture medium containing the microorganism to obtain a concentration of 0.20-0.30 mg/ml, most preferably 0.25 mg/ml.
  • Aliquots are removed from the mixture at defined intervals from duplicate cultures.
  • the processing is preferably done by robotic sample preparation. Processing of the samples includes extraction into an organic solvent, preferably ethyl acetate, centrifugation, sampling of the organic layer and evaporation. The sample is then derivatized with a resolving agent, preferably (S)- ⁇ -methylbenzylamine, to form diastereomeric amides. The amides are then dissolved in the desired solvent, preferably a mixture of acetonitrile/water, for HPLC analysis to assess S-naproxen concentration and enantioselectivity in the hydrolysis of racemic naproxen esters.
  • a resolving agent preferably (S)- ⁇ -methylbenzylamine
  • Isolated standards are run of A,S-naproxen, S-naproxen and the media in which the assay is run. Each sample can be run in duplicate. Standard organisms can also be run to check on the reproducibility of the analysis.
  • a recombinant enzyme is obtained by isolating the ester hydrolase enzyme from a suitable microorganism, e.g., Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis,
  • a suitable microorganism e.g., Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis,
  • Eupenicillium baarnenses Graphium sp . , Heterocephalum aurantiacum, Pencillium roguefortii or Zopfiella latipes, preferably from a Zopfiella strain, more preferably Zopfiella Strain 780: ATCC #44575, determining the amino acid sequence of the isolated enzyme and thereafter cloning and expressing the recombinant enzyme using an E. coli, yeast, such as
  • Saccharomyces cerevisiae or other expression system.
  • Other expression systems that can be used include Bacillus subtilis, Aspergillus niger, and Pichia pastoris.
  • the E. coli bacterium is used for the production of the recombinant enzyme. Cloning and expression can be obtained rapidly in E. coli and high levels of gene expression are common. In addition, production in E. coli results in a system easily scaled up -15-
  • the ester hydrolase from the microorganism can be isolated and purified by standard techniques.
  • the enzyme is purified by a straight forward series of purification steps, i.e. cell disruption, ammonium ⁇ ulfate precipitation, gel filtration, anion exchange chromatography and hydrophobic interaction chromatography.
  • the purified enzyme is then used for determination of the internal amino acid sequence.
  • the internal amino acid sequence of the enzyme is determined by CNBr cleavage and the isolation of the resulting polypeptide fragments, preferably by reverse phase-HPLC.
  • the results provide a partial amino acid sequence (first 10 amino acids at the N-terminal), which aids in the cloning of the ester hydrolase gene.
  • E. coli promoters in addition to the lac promoter include, for example, trp, tac, lambda P L , lambda P R and T7 phage promoter.
  • the molecular cloning of the ester hydrolase gene from the microorganism can be carried out using standard molecular cloning techniques as described in Maniatis, et.al. Molecular Cloning: A Laboratory Manual, 2nd. Edition, Vol.1-3, Cold Spring Harbor Laboratory
  • Double stranded cDNA may be prepared from mRNAs isolated from the microorganism in the manner more completely described in Examples 4 and 6.
  • the cDNA is ligated with ⁇ gt-11 phage DNA suitable for use as a cloning plasmid. After in vitro packaging, the recombinant phage DNA is used to infect an E. coli strain devoid of detectable basal enzyme activity. Plasmid DNA is prepared as more fully described in Examples 4 and 6.
  • a gene encoding the recombinant enzyme is identified from a cDNA library prepared from microorganism by DNA hybridization with polymerase chain reaction (PCR) generated probes using oligonucleotide primers that were based on the partial amino acid sequence previously determined for that microorganism's native enzyme.
  • PCR polymerase chain reaction
  • a subset of the clones, which hybridized positively with the PCR generated probes, should also test positive in the agar-overlay esterase/lipase activity assay as described in Higerd and Spizizen, J.Bacteriol.. 114:1184(1973) , which is incorporated by reference.
  • a complete description of the cloning procedures and confirmation assays used can be found in the examples. -16-
  • the gene is subcloned into a vector, preferably pGEM-13Zf(+) (Promega Corp., Madison, WI).
  • the resulting fusion protein (Seq. I.D. No. 1 and 4) is expressed in high levels in an overnight fermentation of E. coli.
  • the correct identity of a recombinant ester hydrolase gene can be confirmed by determining the DNA sequence of the insert and comparing its inferred amino acid sequence with that previously partially determined for the purified enzyme.
  • the cloned enzyme upon comparison with the natural enzyme isolated from the microorganism, should show identical substrate preference for the S- versus the A-naproxen ester.
  • Activity staining of a recombinant enzyme of this invention preferably a Zopfiella recombinant enzyme, and other commercially available enzymes in a non-denaturing system verifies the enzyme activity of the recombinant enzyme while indicating that the enzymes of the invention are distinctly different from known commercially available enzymes.
  • A,S-naproxen esters a subset of the positive recombinant clones from a microorganism selected from the group Absidia griseola, Aspergillus sydowii, Doratomyces stemonitis, Eupenicillium baarnenses, Graphium sp. , Heterocephalum aurantiacum, Pencillium roguefortii and Zopfiella latipes, preferably Zopfiella latipes, shows activity and evidences enantioselectivity.
  • the enantioselectivity of a recombinant enzyme is confirmed by analyzing hydrolysis products of racemic mixtures of A,S-naproxen esters.
  • the enantioselectivity of the recombinant enzyme from Zopfiella Strain 511 was confirmed by analyzing hydrolysis products of racemic mixtures of methyl, ethyl, and n- propyl naproxen esters.
  • the enantioselectivity of the recombinant enzyme from Zopfiella Strain 780 was confirmed by analyzing hydrolysis products of racemic mixtures of methyl, ethyl, and n-propyl naproxen esters.
  • Table 2 shows that the enantioselectivity of the ester hydrolase enzyme isolated from the Zopfiella Strain 780 (the "780 enzyme"), the ester hydrolase enzyme isolated from the Zopfiella Strain 511 (the "511 enzyme”), the rec 511 enzyme, rec 780 enzyme and rec 780-ml65r210 all yield an average ee of greater than 99%.
  • rec 511, rec 780 and rec 780-ml65r210 enzymes compare favorably with the native enzymes on the basis of their ability to hydrolyze a broad range of naproxen esters with a high enantioselectivity.
  • the Zopfiella enzymes both native and recombinant have been found to be less sensitive towards S-naproxen inactivation than other untreated commercial enzymes.
  • Strain 780 enzyme was shown to be more stable than Strain 511 enzyme towards KNPR inactivation when incubated at about 45°C.
  • a non-ionic stabilizer preferably bovine serum albumin ("BSA") or polyethylene glycol (“PEG”), more preferably PEG 8000, optionally can be added to the reaction mixture containing Zopfiella enzymes (both native and recombinant).
  • BSA bovine serum albumin
  • PEG polyethylene glycol
  • surfactants such as Tween or soybean oil, did not stabilize the Zopfiella enzymes from inactivation by naproxen and formaldehyde treatment did not stabilize the Zopfiella enzymes from inactivation by naproxen.
  • mutagenesis for example, nitrous acid mutagenesis and hydroxylaraine mutagenesis, and other forms of mutagenesis can be employed, including site-directed mutagenesis (Smith, Ann. Aev. Genet, 19:423 (1985)) to enhance thermal stability (Matthews, Biochemistry, 26:6885 (1987)) and S-naproxen stability, the methods of which are known to those skilled in the art. These references are incorporated by reference. Mutagenesis experiments were carried out on the ester hydrolase gene of this invention in an attempt to develop a more thermally stable, tolerant ester hydrolase. These experiments are described in Example 10.
  • ester hydrolase recovered from a mutant with high thermal stability (“rec 780-mlO”) was purified and sequenced to determine the genotype changes. At position 443 of rec 780 the threonine was changed to an isoleucine to give the rec 780-mlO enzyme (Seq. I.D. No. 8 and 9). This specific change gave high thermal tolerance of the rec 780-mlO enzyme as shown in Figure 4.
  • ester hydrolase recovered from a mutant with improved stability to s-naproxen (“rec 780-ml65”) was purified and sequenced to determine the genotype changes.
  • the threonine was changed to alanine
  • the alanine was changed to threonine
  • at position 133 the lysine was changed to arginine
  • at position 330 the valine was changed to leucine
  • at position 400 the threonine was changed to isoleucine in the rec 780 enzyme (Seq. I.D. No. 11 and 12).
  • specific changes were those which gave the rec -19-
  • Ester hydrolase recovered from a mutant (identified as rec 780- ml65r210) with improved stability to KNPR was purified and sequenced to determine the genotype.
  • the threonine was changed to alanine
  • the alanine was changed to threonine
  • at position 133 the lysine was changed to arginine
  • at position 210 the serine was changed to arginine
  • the threonine was changed to isoleucine in the rec 780 enzyme (Seq. I.D. No. 14 and 15).
  • these specific changes were those which gave the rec 780-ml65r210 enzyme high resistance to KNPR inactivation as shown in Table 4, Example 10.
  • the recombinant enzymes of the invention are especially suitable for use in the high yield, low cost production of S-naproxen.
  • the recombinant enzymes can be purified from an E. coli or a yeast culture using various standard protein purification techniques, for example, affinity, ion exchange, size exclusion or hydrophobic interaction chromatography. Active enzyme recovered from such purification techniques can be concentrated using ammonium sulphate, or alternatively, by lyophilization neat or in the presence of sucrose.
  • An exemplary preparation and purification scheme comprises 1) growing the transformed E. coli cells in LB broth and inducing with IPTG; 2) harvesting the culture by centrifugation; 3) resuspending the cell pellet in buffer followed by cell disruption; 4) centrifuging the cell lysate; and 5) purifying the soluble enzyme by passage of the cell ly ⁇ ate over a two-step chromatographic column.
  • Immobilized Enzymes Introduction and Application in Biotechnology, John Wiley, Chichester, UK, (1980)).
  • immobilize cells which contain the enzyme, thereby indirectly immobilizing the enzyme.
  • Such techniques are well known in the art and are described, e.g. Wood, L.L. and Calton, G.J.,"A Novel Method of Immobilization and Its Use in -20-
  • an ester hydrolase as purified enzyme from the microorganism or a ⁇ a recombinant enzyme
  • the Zopfiella enzyme in the production of S-naproxen can be carried out in many formats.
  • the enzyme can be added into a continuous stirred tank reactor. Likewise, it can be immobilized onto matrixes either as immobilized enzyme or a ⁇ host cells containing the enzyme.
  • the enzyme is immobilized on a solid support.
  • the immobilization is carried out by glutaraldehyde binding of the recombinant enzyme to an inert substance, such as silica or the like.
  • the inert ⁇ ubstance is Manville Celite* R-648, R-649 or R-685.
  • Figure 5 shows a schematic of the immobilization process and a description of the immobilization procedure for the isolated enzyme is set forth in Examples 11 and 12. The items identified in Figure 5 are as follows:
  • ho ⁇ t cells such as E. coli, preferably E. coli Strain JM109 or Strain BL21DE3, that express the recombinant ester hydrolase gene are immobilized without isolating the enzyme.
  • the use of whole cells is less expensive and time-consuming than the use of isolated enzyme.
  • the rate of hydrolysis may be stimulated by a biphasic system having organic solvents at about 5% - about 40%(v/v), preferably about 20% to about 25%(v/v).
  • hexane or toluene is used.
  • DMSO may also be used in a monophase system.
  • Example 13 sets forth a description of the intact cell immobilization procedure. -21-
  • Example 13 Table 9 shows the activity of intact E. coli carrying rec 780-ml65r210 immobilized with Polymer 1195 and Polyazetidine.
  • a reactor configuration for using immobilized enzyme to hydrolyze A,S-naproxen esters to S-naproxen in an organic/aqueous solution is in theory, relatively easy to operate. In practice, however, the hydrodynamics of the packed bed reactor require careful control. Focus of attention is on the reactor itself with regards to A,S-naproxen ester concentrations and relative amounts of organic and aqueous phases. Preferably the A,S-naproxen ester concentration is approximately 100-500 g/1 in the organic phase and the relative amounts of organic and aqueous phase are approximately 3:1.
  • A,S-naproxen ester preferably a lower alkyl ester, more preferably ethyl or n-propyl naproxen e ⁇ ter
  • A,S-naproxen ester is introduced continuously into the reactor as a slurry, preferably 50-250 gm per liter.
  • a non-ionic surfactant preferably PEG
  • PEG poly(ethylene glycol)
  • the actual residence time of the enzyme in the enzyme reactor will depend on the substrate infusion rate, the removal rate of the final product and the reaction volume. Preferably the residence time is 12-36 hours.
  • the enzymatic hydrolysis can be conducted in a continuous or batch mode.
  • the reaction is generally carried out at the temperature range between about 30°C and about 65°C, prefer-ably between about 40°C and about 55°C.
  • the incubation temperature should be between about 40°C and about 55°C.
  • a feed reservoir contains water as the aqueous phase and A,S- naproxen ester dissolved in an organic solvent, preferably in an aliphatic solvent.
  • the solvent should have a normal boiling point equal to or greater than water, such as heptane, octane, decane, and dodecane.
  • the preferred solvent is heptane.
  • This biphasic mixture is agitated to keep the phases well mixed.
  • the biphasic mixture is fed to the hydrolysi ⁇ reactor where the S-naproxen ester in the organic phase is hydrolyzed to s-naproxen.
  • the S-naproxen then transfers to aqueous phase and both phases return to the feed reservoir.
  • a base preferably an alkali metal salt, more preferably potassium hydroxide, is added to the feed reservoir to maintain a constant pH of 6-10, preferably 8.0-9.5.
  • KNPR naproxen
  • ethyl or n-propyl naproxen ester is more preferable in the hydroly ⁇ i ⁇ reaction of the invention.
  • the use of the ethyl e ⁇ ter results in the highest enantioselectively a ⁇ shown in Example 9, Table 2 and the n-propyl e ⁇ ter i ⁇ an oil at low temperature ⁇ , allowing greater freedom in the design of a hydroly ⁇ i ⁇ bioreactor.
  • Ethylene glycol based e ⁇ ter ⁇ such as the ethoxyethyl ester, can also be used, as can other ester ⁇ previously described in the ⁇ pecification.
  • S-naproxen the product of the e ⁇ ter hydroly ⁇ i ⁇ , i ⁇ preferably removed from the proces ⁇ stream by passing through a series of filtration membranes that have different and specific molecular weight cut-offs. This avoids the entry of either the unreacted naproxen ester substrate or the recombinant enzyme into the final product.
  • the final product can then be further purified by crystallization.
  • Potential impurities such as a ⁇ , naproxen e ⁇ ter ⁇ , e ⁇ ter hydrolase, proteins, DNA associated with production of the ester hydrolase, etc.
  • Stringent standards for acceptable levels of impurity are established and maintained.
  • the unreacted A-naproxen ester, as well as any residual S-naproxen e ⁇ ter, can be recycled through a separate reactor in which both are racemized chemically.
  • the resultant 50-50 racemic mixture of naproxen ester, as well as fresh A, -naproxen ester, can again be introduced into the bioreactor ⁇ and the processing cycle repeated.
  • the dehydrated Zopfiella(ATCC# 26183) microorganism purchased from ATCC, was rehydrated and plated out on medium 325 to assess growth and purity of the culture by visual inspection.
  • the medium i ⁇ described in R. Cote, ATCC Media Handbook, First Edition, 1984, which is incorporated by reference.
  • a 5% (v/v) inoculum was then added to 25 ml of medium 200 for the assay.
  • 25 ⁇ l of a suspension of 2.5g racemic naproxen ethyl ester in 10 ml sterile soybean oil was added to the medium to a final concentration of 0.25 mg/ml. This mixture wa ⁇ then agitated at 150 r.p.m. at approximately 25 ⁇ C for 48 hour ⁇ .
  • Processing consisted of extraction into ethyl acetate, centrifugation, sampling of the ethyl acetate layer, evaporation, derivatization with ⁇ S)- ⁇ - methylbenzylamine to form the diastereomeric amides and dissolution in a mixture of 80% acetonitrile and 20% water for liquid chromatography.
  • the sample containing 10 ⁇ g/ml was then asses ⁇ ed for KNPR concentration and enantioselectivity by HPLC analysis (Hypersil, 3 micron, 4.6 x 100 mm, C- 18 or equivalent, UV at 235 nm, 0.2 alssd) .
  • Enzyme from Zopfiella (ATCC #26183: Strain 511) wa ⁇ prepared from 3- day cultures by cell lysi ⁇ in a bead beater, removal of cell wall debris by centrifugation, and concentration by ammonium sulfate precipitation (40-60% saturation). The pellet was redissolved in 10 ml of 20 mM Trie HCl/1 mM EDTA pH 8 buffer, loaded on and eluted from a Sephacryl HR300 gel filtration column (Pharmacia, Piscataway, NJ) with 50 mM Tris HCl/1 mM EDTA pH 8.
  • Enzyme from Zopfiella (ATCC #44575: Strain 780) was prepared from 2- day cultures using the procedure essentially a ⁇ described in Example 2(A).
  • Activity gels showed a single, active protein band that corresponded to the protein on the SDS-PAGE gels at a molecular weight of approximately
  • the internal amino acid sequence of the Strain 511 enzyme wa ⁇ determined by CNBr cleavage and the isolation of the nine resulting polypeptide fragments by reverse pha ⁇ e-HPLC.
  • a purified preparation of the enzyme wa ⁇ electrophore ⁇ ed on a SDS-polyacrylamide gel.
  • the resolved protein band(s) were then electro-blotted onto an Immobulon filter (Millipore Corporation, Medford, MA) and the protein band of interest was cut out and subjected to the standard micro-sequencing technique as described in Matsudira, J. Biol . Chem. 262 :10035 (1987), which i ⁇ incorporated by reference.
  • the products were then analyzed on an automated gas-phase micro ⁇ equentor (Applied Bio ⁇ ystem Inc., Foster City, CA) using the methods a ⁇ described by Hunkapellier et al. , Meth. Enz. ,
  • Zopfiella (ATCC #26183: Strain 511) was propagated in YM broth using sheared glas ⁇ broken mycelia a ⁇ seed to provide uniform growth. The mycelia were harvested by filtering through sterile gauze after 2-3 days of growth and prior to asci formation according to the methods of Davis and DeSerres, Methods of Enzymology, Vol.17a (1970) and Weigel et al . , J. of Bacteriol . , 170 (9 ) :3187 (1988), which are incorporated by reference.
  • Zopfiella mycelia were pulverized under nitrogen by mortar and pestle.
  • mRNA was prepared according to Chirgwin, Biochem. , 18: 5294 (1979), which i ⁇ incorporated by reference.
  • Frozen Zopfiella cells were re ⁇ u ⁇ pended in buffer containing 4 M guanidinium thiocyanate, 0.5% ⁇ odium N-lauryl ⁇ arco ⁇ ine, 25 mM sodium citrate and 0.1 mM ⁇ -mercaptoethanol.
  • the suspension was Polytron (Brinkmann Instruments Inc., Westbury, N.Y.) treated twice at 30 ⁇ econd ⁇ each. The lysate was repeatedly drawn into a hypodermic syringe fitted with a 18 gauge needle and then expelled into polypropylene tubes. This was repeated 10 times to shear the cellular DNA.
  • RNA pellet was re ⁇ u ⁇ pended in 10 mM Trie HCl/0.1 mM EDTA pH 7.4 buffer containing 0.1% SDS and immediately extracted with hot phenol (65°C).
  • RNA recovered from the aqueous phase wa ⁇ extracted with phenol and chloroform. The RNA wa ⁇ then precipitated with ethanol.
  • a cDNA library was constructed using a Promega Riboclone Kit (Madison, WI) and an Invitrogen Kit (San Diego, CA) .
  • the second ⁇ trand synthesis was carried out using an Invitrogen Kit
  • reaction was then heat denatured at 70°C for 10 min and set at room temperature for 2 min. After the addition of T 4 DNA polymerase (27 Units), the reaction wa ⁇ further incubated for 10 min at 37°C. The reaction wa ⁇ then extracted with phenol/CHCl 3 .
  • reaction wa ⁇ adju ⁇ ted to IX Not I buffer (NEB, Beverly, MA), 100 ⁇ g/ml BSA, and 5 ⁇ M ATP.
  • IX Not I buffer NEB, Beverly, MA
  • T 4 polynucleotide kina ⁇ e 10 Unite
  • Not I 30 Unite
  • the reaction wa ⁇ incubated at 37°C for 60 min followed by a second incubation with Not I (30 Units) for 60 min.
  • DNA samples following phenol/CHCl 3 extractions were purified using Promega CE802 Spin columns (Madi ⁇ on, WI) and ethanol-precipitated.
  • In vitro phage packaging was carried out using a "Gigapack Gold Extract" according to the vendor's protocol (Stratagene, La Jolla, CA) .
  • E. coli LE392 infected with the in vitro packaged phage ⁇ were plated onto NZY plates in NZY soft agar.
  • E. coli Y1090 cells were used and plated onto LB plates in LB soft agar containing 1.2 mM IPTG and 0.07% X-gal.
  • the packaging efficiency of recombinant phage ⁇ was about 1-2 X 10* pfu per ⁇ g of lambda arms.
  • PCR products were generated u ⁇ ing an USB GeneAmp Kit (Perkin Elmer Cetu ⁇ , through United States Biochemical, Cleveland, OH).
  • Oligonucleotide primers (10 pmole ⁇ each) were mixed with 250 ng of genomic DNA in buffer containing 10 mM Trie HCl, pH 8.3, 50 mM KC1, 1.5 mM MgCl 2 , 0.01% gelatin and 250 ⁇ M dNTP ⁇ . 1.25 units of AmpliTaq DNA polymerase was added to the reaction. Temperatures for annealing were increased step-wise: 4 cycles at 37°C, 3 cycles at 43°C and 26 cycles at 50°C. All extensions were performed at 72°C for 3 min except for the last 50°C annealing cycle which wa ⁇ for 10 min. Between cycle ⁇ , reactions were denatured at 94°C for 2.5 min in the very first cycle and 1 min in all subsequent cycles.
  • PCR products generated by one set of primers were probed with radioactively labelled PCR products generated by another set of primers, certain common fragments showed positive hybridization. Ba ⁇ ed on the intensity and simplicity of hybridization pattern, PCR products generated by primers 1 + 6 and 2 + 7 were regarded as most likely to be specific for the Zopfiella ester hydrolase gene.
  • the phage plaques were induced with IPTG and assayed in situ for ester hydrolase activity. If the open reading frame of the e ⁇ ter hydrolase gene wa ⁇ in the same translational reading frame a ⁇ the lac gene and without interruption by stop codons within the 5' untranslated region, a functional e ⁇ ter hydrola ⁇ e would be produced, a ⁇ evidenced by the development of purple color when the phage plaques were overlaid with soft agar containing ⁇ -naphthyl-acetate and fast blue BB salt (Sigma, St. Louis, MO) (Higerd and Spizizen, supra, (1973)).
  • Figure 3 shows the junction sequences between the Zopfiella cDNA and the plasmid vector.
  • the cDNA inserts are in the same translational reading frame as the lac sequence.
  • the 5* portion of the cDNA molecule encodes amino acid ⁇ which correspond to those previously determined for the N terminus of the purified Zopfiella e ⁇ ter hydrola ⁇ e.
  • the complete DNA sequence for the Zopfiella ester hydrolase gene (clone 1-2) was subsequently determined using an Applied Biosystem DNA ⁇ equenator (Applied Bio ⁇ y ⁇ tem ⁇ , Inc., Foster City, CA). The complete DNA sequence as identified is set forth as Seq. I.D. No. 12.
  • E. coli cells harboring the pGEM-13Zf(+)/enzyme plasmid ⁇ were propagated overnight in LB broth in the presence of 1 mM IPTG. The cells were harvested by centrifugation and disrupted by sonication. After centrifugation at 10,000 rpm for 30 min (JA20 rotor), the supernatant ⁇ were assayed for enzyme activity.
  • Enzyme activity was measured using the S-enantiomer of p-nitrophenyl naproxen ester (5-PEN). Hydrolysi ⁇ of S-PEN was carried out at 37°C in a 1 ml reaction consisting of 50 mM NaMOPS pH 7.5, 50 ⁇ g BSA, 1-5 ⁇ g extract and 20 ⁇ l of 100 mM S-PEN in DMSO. The reaction was terminated when visible yellow color appeared (approximately 20 min) by placing the reaction in a dry ice bath. The reaction was thawed and centrifuged at
  • clone (1-2) When the protein extracts were analyzed by SDS-PAGE, clone (1-2) also showed a prominent protein band at about 46 kD.
  • the rec 511 enzyme ha ⁇ a major protein band of approximately 46.5 kD which i ⁇ slightly larger than the naturally occurring Strain 511 enzyme.
  • the migration rate of the recombinant protein is slightly slower in native gels than the authentic fungal derived 511 enzyme.
  • Example 2(a) Upon further purification a ⁇ de ⁇ cribed in Example 2(a), the 46.5 kD protein wa ⁇ subsequently shown to have good enzyme activity. Moreover, it preferentially hydrolyzed S-naproxen e ⁇ ter ⁇ a ⁇ de ⁇ cribed in Example 9.
  • a cDNA library was constructed using mRNA isolated from Zopfiella
  • Enzyme activity wa ⁇ assayed using methodologies identical to that de ⁇ cribed in Example 5.
  • the purified Strain 780 enzyme like the Strain 511 enzyme had a major protein band that migrated at a rate consistent with a 46.5 kD size protein.
  • the two activity bands associated with the purest preparation migrated with an f number of 0.67 and 0.56.
  • the slower migrating protein R f - 0.56 is believed to be either a breakdown or deaminated product of the 46.5 kD protein. Alternatively, it can be another unrelated nonspecific enzyme.
  • Yeast shuttle plasmid pSRF137 was constructed to allow galacto ⁇ e- inducible expression of the Zopfiella 511 enzyme in Saccharomyces cerevisiae.
  • Figure 1(b) sets forth a diagram of the expression plasmid construction.
  • cDNA from clone 1-2 ( Figure 3) was first subcloned into the Sma I site of pUC18, creating pSRF115, by digesting with Eco RI and Not I, and treating with the Klenow fragment of DNA polymerase.
  • the cDNA was excised from pSRF114 a ⁇ a Bam HI-A ⁇ p718I fragment and inserted between the BAM HI and A ⁇ p718I site ⁇ of pSEY303 to create pSRF16, as described by Emr, Douglas, J. Cell Biol. , 102:523 (1986), which in incorporated by reference.
  • pYRF102 i ⁇ a 2 ⁇ -ba ⁇ ed shuttle plasmid that contains LEU2 and URA3 selectable markers, the GAL4 gene, and the GAL1 regulatory region promoter with a unique Bam HI site about 65bp distal to the transcription initiation site as described in U.S. Patent No. 4,661,454, which is incorporated by reference.
  • Yeast cells (DA2102) Barnes, D.A. and J. Thorner, Mol. Cell. Biol . 6:2828 (1986) were grown and plasmid pSRF137 selection was maintained in media lacking uracil (0.67% Yeast Nitrogen Base without amino acid ⁇ (Difco), 0.5% vitamin-assay Casamino acid ⁇ (Difco), 50 ⁇ g/ml adenine . ⁇ ulfate, 40 ⁇ g/ml hi ⁇ tidine hydrochloride, and 25 ⁇ g/ml tryptophan).
  • Non-inducing media was supplemented with 2% gluco ⁇ e wherea ⁇ inducing media -32-
  • Extracts were prepared by disrupting cells with glass beads, as modified from a previously described procedure in Asubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl, ed., Current Protocols in Molecular Biology. , New York: Greene publishing and Wiley-Inter ⁇ cience, 1991, which is incorporated by reference.
  • Cell pellet ⁇ were re ⁇ u ⁇ pended in ice cold MOPS buffer (1 ml for each 10,000- 12,000 klett unite) and 0.25 to 0.6 ml aliquots were placed in 1.5 ml microfuge tubes and 1 ⁇ l antifoam A.(Sigma, St. Louis, MO) was added.
  • a line wa ⁇ drawn on these tube ⁇ to indicate the volume occupied by the cell su ⁇ pen ⁇ ion and gla ⁇ bead ⁇ were added until they reached this line.
  • the tube ⁇ were then vortexed for 12 min alternating 20 sec of vortexing with 20 sec on ice. Tubes were then centrifuged for 1 min at 10 k x g (4°C). The supernatant was removed and assayed for protein and enzyme activity.
  • the protein concentration of the extracts was determined either by a Bradford Bio-Rad Protein Assay (BioRad Laboratories, Richmond, CA) or Pierce BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL) assay using BSA a ⁇ a standard. Enzyme activity wa ⁇ mea ⁇ ured using either the S-enantiomer of p-nitrophenyl naproxen ester (S-PEN) or racemic naproxen ethyl e ⁇ ter.
  • S-PEN S-enantiomer of p-nitrophenyl naproxen ester
  • racemic naproxen ethyl e ⁇ ter racemic naproxen ethyl e ⁇ ter.
  • Non-denaturing gel ⁇ contained 12.5% acrylamide (acrylamide:bis i ⁇ 30:0.8) and 370 mM Trie HCl pH 8.8 in the running buffer and 4% acrylamide, 125 mM Tris HCl pH 6.8 in the ⁇ tacking buffer.
  • Running buffere contained 37.7 mM Trie HCl, 40 mM glycine pH 8.9 in the top re ⁇ ervoir; and 62.5 mM Trie HCl pH 7.5 in the bottom reservoir.
  • Gels were stained for lipase activity using a ⁇ -naphthyl acetate- fast blue assay. The gels were incubated for 15 min at room temperature in 100 ml of NaPi pH 7.4, 5 ml isopropanol, 0.4 mg/ml fast blue (Sigma F- 0500), 0.03% ⁇ -naphthyl acetate (Sigma N-6875, 1.5 ml of a prepared/2% solution in acetone). Gels were subsequently destained in 7% acetic acid.
  • Proteine were eluted from non-denaturing gel ⁇ using an in situ gel -33-
  • Hydroly ⁇ i ⁇ of ethyl ester was carried out at 37°C in a 1 ml reaction consisting of 50 mM NaPi pH 8.5, 50 ⁇ g BSA, 1-5 ⁇ g extract, and 20 ⁇ l of
  • P ⁇ lyclonal antisera to the Zopfiella ester hydrolase were prepared by injecting rabbits with recombinant or native enzyme (initial injection, 0.1 mg subcutaneous in complete Freund's adjuvant; subsequent boo ⁇ t ⁇ , 0.5 mg IM in incomplete Freund's adjuvant).
  • the eluted band was ⁇ ubjected to SDS-polyacrylamide gel electrophoresis along with the crude extracts from the pSRF137 and control strains.
  • the eluted band contained a single 43 kD species, the molecular weight predicted from the DNA sequence of the Zopfiella enzyme. Together with the amino-terminal sequencing, the ⁇ e data suggest that the yeast- derived enzyme i ⁇ unmodified and ha ⁇ the expected carboxy terminus.
  • yeast-derived enzyme was shown to be slightly ⁇ maller than the recombinant enzyme produced in E. coli which i ⁇ expre ⁇ ed with a 3 kilodalton fusion partner, as expression in yeast results in a full length authentic enzyme.
  • Each enzyme was incubated with 5 mg/ml of solid A,S-EtNPR or MeNPR and 20% (v/v) of the liquid A,S-PrNPR at 42°C in 0.1 M Tris HCl/0.2% PEG 8000 pH 8.0 overnight.
  • the hydrolysate was diluted 1:3 in 50 mM KH 2 P0 4 and ultrafiltered through a 3000 MWCO membrane (Centricon microconcentrator, Amicon, Beverly, MA). The filtrate was analyzed on a chiral HPLC column (Chiral AGP Column, ChromTech, Sweden) using procedures recommended by the manufacturer.
  • Strain 511 enzyme wa ⁇ harve ⁇ ted from a 3-day culture and prepared by 30%-60% ammonium ⁇ ulfate fractionation, followed by DEAE and hydrophobic interaction chromatography a ⁇ described in Example 2(A).
  • Strain 780 enzyme was harvested from a 2-day culture and prepared by 30%-60% ammonium ⁇ ulfate fractionation, followed by DEAE and hydrophobic interaction chromatography a ⁇ described in Example 2(B).
  • Rec 511, rec 780 and rec 780-ml65r210 enzymes were obtained from an overnight E. coli fermentation in LB broth and were concentrated with a 30%-60% ammonium sulfate precipitation, followed by purification with DEAE and size exclusion HPLC.
  • the ee values given in Table 2 are not corrected for background levels of racemic acid.
  • the levels of background acid are methyl e ⁇ ter»n-propyl ester>ethyl ester and may well account for the differences in ee' ⁇ between these naproxen alkyl esters.
  • the Zopfiella enzymes studied showed an enantioselectivity of greater than 98%. -35-
  • a comparison of the ability of Zopfiella Strain 511 e ⁇ ter hydrola ⁇ e to hydrolyze ethyl and n-propyl naproxen ester was carried out.
  • a 2.5 ml solution of heptane containing 2% ethyl A,S-naproxen ester was mixed with 2.5 ml of 0.1 M Tris HCl, pH 8.0.
  • the reaction was started by adding 200 ⁇ l of Zopfiella Strain 511 unpurified ester hydrolase solution (16 mg dry weight/ml) to the appropriate reaction mixture.
  • the pSELECT-1 vector containing the 780 gene will be hereinafter referred to as "pS780".
  • pSELECT-1 DNA contains lac operon sequences and tran ⁇ formant ⁇ show ⁇ -galactosidase activity.
  • pS780 wa ⁇ transformed into E. coli JM109 cells. The cells were then infected with helper phage R408 (Promega) to generate single stranded DNA copies of pS780. The single stranded pS780 was packaged into phage, harvested, and isolated.
  • the isolated DNA was treated with 0.2 M nitrous acid for 15 minutes at room temperature.
  • the single stranded DNA wa ⁇ primer extended using a T7 primer and AMV reverse tran ⁇ cripta ⁇ e in the presence of deoxynucleotides.
  • the mutated 780 gene wa ⁇ excised by Hind III/Bam HI digestion and gel purified and then ligated into gel purified Hind III/Bam HI digested p-SELECT-1.
  • the mutagenized single stranded DNA wa ⁇ then transformed into E. coli JM109. Tran ⁇ formant ⁇ generated were replica plated into LB + tetracycline (15 ⁇ g/ml) + IPTG (1 mM) medium. The replica platea were allowed to grow overnight at 37 ⁇ C.
  • the pSELECT-1 plasmid offered an easy way to determine the effectivene ⁇ of the mutagenesis.
  • Cells grown on solid medium in the presence of i ⁇ opropylthiogalacto ⁇ ide (IPTG) and 5-Bromo-4-chloro-3- indolyl- ⁇ -D-galactopyrano ⁇ ide (X-gal) formed easily recognizable blue colonies. If ⁇ -galactosida ⁇ e was inactivated through mutation, the colonies were white. -37-
  • Replica plates containing 200-700 colonies were heated at 55°C for several hours. The plates were then cooled to room temperature and overlaid with 0.5% agaro ⁇ e containing ⁇ -naphthyl acetate and the indicator fast blue. Ester hydrolase activity was indicated by the colonies turning a red-purple color. Colonies showing the most rapid color changes were restreaked onto the same medium. After outgrowth, the plates were replicated and the replates examined again for enzyme activity after heating at 55°C for up to 7 hours.
  • Enzyme inactivation kinetics of cells transformed with mutant DNA were compared with those of non-mutant pS780 transformed cells.
  • Cell extracts in 0.2% PEG 8000 and 0.1 M Trie HCl, pH 8.0
  • samples were taken and assayed for activity using the S-PEN assay.
  • the mutant enzyme retained approximately 45% of its original activity, while the non-mutant enzyme had lost almost all activity.
  • the DNA from the mutant enzyme rec 780-mlO was then purified and sequenced to determine genotype changes.
  • thermostable mutants Resistance to KNPR inactivation of thermostable mutant ⁇ wa ⁇ compared with that of non-mutant ⁇ by incubating cell extracts at 45 ⁇ c in the presence of KNPR at 20 g/1 and 33 g/1. At various times, samples were taken and assayed for enzyme activity by the S-PEN method. Ester hydrolase activity wa ⁇ more stable with the mutant extracts than with the non-mutant extracts when incubated with 20 g/1 KNPR. At 33 g/1 KNPR, the mutant extract was rapidly inactivated.
  • Thermostable mutants were subjected further to nitrous acid mutagenesis as de ⁇ cribed above.
  • the mutated DNA wa ⁇ made double stranded, excised, and ligated into the appropriate vector.
  • E. coli JM109 was transformed and about 200,000 transformants were obtained.
  • Replicas were made onto LB plates supplemented with 15 ⁇ g/ml tetracycline and 0.5 mM IPTG. After grow out, the plates were incubated at 60°-65°C for various lengths of time and subsequently screened for enzyme activity using the ⁇ - naphthyl acetate overlay method. Mutants that exhibited strong temperature stability were isolated and screened for stability in the -38-
  • mutants were isolated that exhibited ⁇ tability in the presence of 33 g/1 KNPR at 45°C. Therefore, the second generation of mutant ⁇ were much more KNPR resistant than the original pS780.
  • thermostable mutants were prepared using the above procedure.
  • Third-generation mutant ⁇ exhibited enzyme ⁇ tability in the presence of 40 g/1 KNPR at 40°C.
  • Fourth- generation mutant ⁇ similarly prepared, exhibited enzyme ⁇ tability in the presence of 60 g/1 KNPR at 40°C.
  • E. coli JM109 containing rec 780, rec 780-ml65 and rec 780-ml65r210 were grown overnight in LB broth supplemented with IPTG (1 ⁇ m) and tetracycline (15 ⁇ g/ml).
  • the cells were harvested, suspended in 1 ml of 0.1 M Trie HCl, pH 8.0, supplemented with 0.2% PEG 8000 and disrupted by vigorous agitation in the presence of glass beads. Cellular debris and glass beads were removed by centrifugation (10,000 x g for 10 min).
  • Inoculum wa ⁇ started from frozen seed stocks of Zopfiella ⁇ tored at -70°C in 20% glycerol. One vial was thawed and inoculated into the basal media containing 0.6% gluco ⁇ e (w/v) , 5 g/1 (NH 4 ) 2 P0 2 , 6 g/1 Na*jHP0 4 , 3 g/1 KH 2 P0 4 , 1.1 g/1 Na 2 S0 4 , 5 mg/1 thiamine, 500 mg/1 MgS0 4 7H 2 0, 100 mg/1 ampicillin and 0.5 ml/1 trace metal ⁇ olution. The culture wa ⁇ incubated in a baffled fla ⁇ k on a rotary ⁇ haker at 37°C for 7-8 hour ⁇ . The cells -39-
  • the fermentor was inoculated with these cells at a concentration of 1 part to 20 parts of minimal medium. Specifically, eight liters of basal medium are inoculated with 400 ml of the ⁇ eed.
  • Dissolved oxygen is maintained at 20-40% through control of agitation speed and addition of supplemental oxygen.
  • the pH i ⁇ regulated at 6.9-7.0 by addition of 5N NH 4 OH.
  • Feed ⁇ olution #1 400 g/1 gluco ⁇ e, 10 g/1 MgS0 4 .7H; 2 ⁇ and 100 mg/1 thiamine i ⁇ added at a rate to maintain the gluco ⁇ e concentration at 1-3 g/1.
  • the E. coli culture was then induced (lac promoter of the plasmid is induced) with 1 mM IPTG when the cell density reached an absorbence of .20 at 550 nm.
  • the feed streams were discontinued at thi ⁇ time and the culture wa ⁇ harve ⁇ ted five to six hours post induction.
  • the cells were then concentrated by centrifugation.
  • the cells can also be concentrated by cross filtration.
  • the cell lysate including insoluble cellular debris, wa ⁇ extracted in 17% (w/v) PEG 1550, 8% (w/v) ⁇ odium pho ⁇ phate and 20% (weight wet cells prior to disruption/v) biomass. After mixing for 20 minutes, the mixture was centrifuged at 2000 rpm. Eighty percent of the enzyme partitions to the upper PEG rich phase. The PEG was removed from the enzyme utilizing ultrafiltration (30,000 molecular weight cutoff, Amicon spiral cartridge).
  • v/v in DI water wa ⁇ prepared with the pH between 3 and 4. The pH was adjusted with 1.0 N HCl or 1.0 N KOH. To the flask was added 300 ml of 10% silane ⁇ olution per gram of Celite. The fla ⁇ k wa ⁇ evacuated ⁇ everal time ⁇ to en ⁇ ure that the pores were liquid filled. The flask was heated to 70°C and held at that temperature for three hour ⁇ . The acid washed- silanized Celite was cooled to room temperature, washed extensively with DI water and dried in a vacuum oven at 70°C.
  • the enzyme can be added to wet support after washing with DI water.
  • the enzyme solution contained 1.0 mg/ml protein in 50 mM Bicine buffer at a pH of 8.5.
  • the surface moisture was removed from the support by vacuum filtration.
  • the mixture wa ⁇ then washed three times with 50 ml of 50 mM Bicine buffer.
  • the wet support wa ⁇ then transferred to the hydrolysis bioreactor.
  • the first immobilization technique used was glutaraldehyde linking of the Zopfiella enzyme to a ⁇ ilica ⁇ upport.
  • the support used was Manville Celite* R-648 comprised of spherical particles of -30+50 mesh with a surface area of 46 m 2 /g>
  • the procedure for support preparation and enzyme attachment was as described above.
  • the immobilization variables were investigated. The first was the glutaraldehyde concentration used for grafting to the silanized support.
  • the second variable wa ⁇ the amount of protein that could be attached to the glutaraldehyde-grafted ⁇ upport. Ba ⁇ ed on the surface area of the support and an estimate of the ⁇ ize of an enzyme molecule, it wa ⁇ estimated that the maximum protein loading on the substrate, assuming monolayer formation, was in the range of 0.2 to 0.4 mg/m 2 .
  • the initial immobilization wa ⁇ performed with protein loading below and above this range. -41-
  • Table 5 summarize ⁇ the re ⁇ ult ⁇ of the immobilization experiments.
  • a control was used in which the ⁇ upport was silanized, but not treated with glutaraldehyde prior to incubation with the enzyme.
  • the enzyme u ⁇ ed wa ⁇ the 40-60% ammonium ⁇ ulfate fraction (Fraction II) recovered from the crude lysate.
  • the experiments were conducted by adding 8.0 g of the immobilized enzyme to 50 ml of 0.05 M KH 2 P0 4 containing 500 ppm of PEG 8000 (Sigma, St. Louis, MO). After the aqueous phase was heated to 40°C and the pH adjusted to 8.5, 10.0 ml of heptane containing 1.63 g PrNPR was added. The reaction was allowed to proceed for 24 hours. The aqueous phase wa ⁇ sampled for S-naproxen analy ⁇ i ⁇ , including concentration and ee. Table 6 summarizes the results of the hydrolysis experiments with the immobilized enzyme preparations. -42-
  • EXAMPLE 12 Use of the Zopfiella rec 511 enzyme in a bioreactor for production of S-naproxen
  • the reaction can be carried out using soluble enzyme.
  • the reaction mixture wa ⁇ maintained at room temperature and the pH maintained at 8.0 by the addition of 1.0 M KOH. After 28 hours of hydroly ⁇ i ⁇ , the organic and aqueous phases of the reaction were separated in a separatory funnel.
  • the KNPR content in the aqueous phase was measured by HPLC using a Hyper ⁇ il C8 column (Alltech, Deerfield, II).
  • the optical purity of the KNPR was measured by chiral HPLC using a chiral AGP column(ChromTech, Sweden) .
  • the unreacted ester was recovered from the hexane by evaporation and analyzed for optical purity using the same chiral HPLC column.
  • the aqueous phase contained 13.2 g/1 naproxen a ⁇ the potassium salt with an enantiomeric excess of 99.0%.
  • Thi ⁇ represented an A,S-e ⁇ ter conversion of 35.0%.
  • the unreacted n-propyl e ⁇ ter of naproxen contained 68.2% of the A-enantiomer and 31.8% of the S- enantiomer.
  • E. coli cell ⁇ carrying the rec 511 gene, and cells carrying the rec 780 gene were grown overnight in LB broth supplemented with 100 ⁇ g/ml ampicillin, harvested, and ⁇ u ⁇ pended in di ⁇ tilled water.
  • the cell ⁇ were permeabilized with 1% v/v toluene.
  • the permeabilized cell ⁇ were then mixed with an equal volume of polyazetidine.
  • the pH wa ⁇ maintained around pH 8.0 by adding a email volume of 1.0 M NaOH.
  • the mixture wa ⁇ then poured into a plastic container and a vacuum wa ⁇ pulled. After a short period of vigorous bubbling, the su ⁇ pen ⁇ ion solidified into a wafer.
  • the wafer was ground into a powder using a coffee mill.
  • the cells were assayed for n- propyl naproxen e ⁇ ter hydroly ⁇ i ⁇ at 35°C in the pre ⁇ ence of 25% v/v hexane.
  • This wa ⁇ done by adding varying amounts of immobilized cells to flasks containing 15 ml of 0.1 M Tris HCl buffer, pH 8.0 containing 0.2% PEG 8000 and 25% v/v hexane containing 100 mg of PrNPR. Samples of the aqueous phase were taken at various times and analyzed for naproxen concentration by HPLC using a Hyper ⁇ il C8 column. The results of these hydroly ⁇ i ⁇ experiments are shown in Table 7. The immobilized cells hydrolyzed n-propyl naproxen ester at rates dependent upon catalyst concentration.
  • Stability of the immobilized cells in KNPR was determined by adding 200 mg of immobilized cell ⁇ to 13 ml of 1 mM Trie HCl buffer, pH 8.0 containing 0.2% PEG 8000 and 48.75 g/1 KNPR, and 4.0 ml DMSO. After the enzyme wa ⁇ allowed to stand in this ⁇ olution at room temperature for ten minutes, 2 ml of PrNPR was added to the flask and the pH monitored with -44-
  • E. coli JM109 carrying rec 780-ml65r210 was suspended to an optical density of 20 at 620 nm in 120 ml of 0.1 M Tris HCl containing 0.2% PEG 8000.
  • the flocculated cell ⁇ were then pelleted by low speed centrifugation and the resulting pellet ⁇ were combined, pressed and dried overnight at 37°C. This material wa ⁇ then cut into thin strips, dried for an additional 24 hours at 37°C and cut into email pellet ⁇ (approx. 1 mm).
  • the reaction mixture contained 100 mM of 3 mm Trie HCl, 0.2% PEG 8000, 15 ml of PrNPR and 1 g of the pellet ⁇ .
  • the reaction was carried out at 37°C and a pH of 7.9 was maintained by adding 20% KOH to the reaction mixture.
  • the results of this study are presented in Table 9. -45-
  • Example 11 the reaction can be carried out using soluble enzyme.
  • To this fla ⁇ k wa ⁇ added 7,800 Unite of the recombinant enzyme, rec 780-ml65r210, in 22.4 ml of 30 mM Trie HCl buffer.
  • the reaction mixture wa ⁇ maintained at 50°C and the pH wa ⁇ maintained at 8.5 by the addition of 1.0 M KOH. After 24 hours of hydroly ⁇ i ⁇ , the reaction ⁇ lurry was separated by filtration.
  • the aqueous phase contained 30.1 g/1 of S-naproxen a ⁇ the potassium salt with an ee of 99.3%. This represented a conversion of 39.0%.
  • MOLECULE T ⁇ PE protein
  • HYPOTHETICAL NO
  • ANTI-SENSE NO
  • ATC ⁇ CTTCC ⁇ TC ⁇ CC ⁇ CC ⁇ T CAAGATGCCT CC ⁇ CCGTCCG GCGCCGGCTC C ⁇ TC ⁇ CC ⁇ TC 180
  • TC ⁇ CCTCCT CCTTC ⁇ CTTT CTCCTCCGCC GCGGGC ⁇ CTC G ⁇ CTCTTCT CTC ⁇ GG ⁇ GA ⁇ 300 ⁇ CCGTCCCTC AGGCCCTCG ⁇ CG ⁇ CGTCCTC T ⁇ CCTCGCCT CCGCCACCAA ACTCCTGGCC 360
  • TCCCTCCTGA CTC ⁇ CTCCTC GGG ⁇ TG ⁇ TC T ⁇ CGATTTCT TCGACCCCGG CGGGCTCGTC 600
  • G ⁇ TC ⁇ T ⁇ TCC GCGAG ⁇ G ⁇ T C ⁇ TC ⁇ GGCC GTTGGCGGG ⁇ ⁇ CCCTGCCG ⁇ TGCGG ⁇ GTTT 840
  • GATATTTATC GGGTT ⁇ GAGA GGCTTGG ⁇ G GCTAGTGGGG GTGGG ⁇ GG ⁇ GGAGTAAGTA 1440
  • G ⁇ G ⁇ TCC ⁇ T CCGCT ⁇ TCTC ⁇ GGCGTC CTC ⁇ TGGTG CC ⁇ TCCTCCT CGCC ⁇ CTG ⁇ C 240
  • TC ⁇ CCTCCT CCTTC ⁇ CTTT CTCCTCCGCC GCGGGC ⁇ CTC G ⁇ CTCTTCT CTC ⁇ GG ⁇ G ⁇ 300 ⁇ CCGTCCCTC AGGCCCTCGA CG ⁇ CGTCCTC T ⁇ CCTCGCCT CCGCC ⁇ CC ⁇ ACTCCTGGCC 360
  • ATCATCGTCC CGG ⁇ TTG ⁇ C CTCC ⁇ G ⁇ GTCTTC ⁇ G GCTGGTCCG ⁇ CGCC ⁇ CCTCC 480
  • TCCCTCCTGA CTC ⁇ CTCCTC GGG ⁇ TG ⁇ TC T ⁇ CG ⁇ TTTCT TCGACCCCGG CGGGCTCGTC 600
  • GATCATATCC GCGAGAGA ⁇ T CATCAAGGCC GTTGGCGGGA ACCCTGCCGA TGCGGAGTTT 840
  • GAGATTGTAG ⁇ GGCGGG ⁇ GC ⁇ GGCG ⁇ GT TATTAGAATA GTTATTATTC AGATACATTC 1560
  • TCCCTCCTGA CTCACTCCTC GGGAATG ⁇ TC T ⁇ CG ⁇ TTTCT TCG ⁇ CCCCGG CGGGCTCGTC 600
  • MOLECULE TYPE CDNA
  • HYPOTHETICAL YES
  • ANTI-SENSE NO
  • MOLECULE TYPE protein
  • HYPOTHETIC ⁇ L NO
  • ANTI-SENSE NO
  • ATCATCGTCC CGG ⁇ TTG ⁇ C CTCC ⁇ G ⁇ GTCTTC ⁇ G GCTGGTCCG ⁇ CGCC ⁇ CCTCC 480
  • GATATTTATC GGGTT ⁇ G ⁇ G ⁇ GGCTTGGAAG GCT ⁇ GTGGGG GTGGG ⁇ GG ⁇ GG ⁇ GT ⁇ GT ⁇ 1440
  • GAGATTGTAG ⁇ GGCGGG ⁇ GC ⁇ GGCG ⁇ GT T ⁇ TTAGAATA
  • GTTATTATTC ⁇ G ⁇ T ⁇ C ⁇ TTC 1560
  • TGGTATGGCA AGGGG ⁇ CT ⁇ T GAGTTGGGGC GGCGGGCATA CATTGGTTTG GTTTATCGAT 1140

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention décrit l'hydrolyse enantiosélective d'esters de naproxène racémiques par des esters hydrolases, les hydrolases étant dérivées d'un groupe de micro-organismes dont le plus approprié était le micro-organisme, Zopfiella latipes. Les esters hydrolases sont utilisés dans une hydrolyse d'esters de naproxène racémiques dont le coût est faible et le rendement élevé.
EP93911192A 1992-05-15 1993-05-14 PROCEDE ENZYMATIQUE POUR LA PRODUCTION D'ACIDE $i(S)-6-METHOXY-ALPHA-METHYLE-2 NAPHTALENACETIQUE Withdrawn EP0644940A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88365892A 1992-05-15 1992-05-15
US883658 1992-05-15
PCT/US1993/004392 WO1993023547A1 (fr) 1992-05-15 1993-05-14 Procede enzymatique pour la production d'acide s-6-methoxy-alpha-methyle-2 naphtalenacetique

Publications (1)

Publication Number Publication Date
EP0644940A1 true EP0644940A1 (fr) 1995-03-29

Family

ID=25383055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93911192A Withdrawn EP0644940A1 (fr) 1992-05-15 1993-05-14 PROCEDE ENZYMATIQUE POUR LA PRODUCTION D'ACIDE $i(S)-6-METHOXY-ALPHA-METHYLE-2 NAPHTALENACETIQUE

Country Status (5)

Country Link
EP (1) EP0644940A1 (fr)
FI (1) FI945353L (fr)
MX (1) MX9302853A (fr)
NO (1) NO944336D0 (fr)
WO (1) WO1993023547A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304351D0 (en) * 1993-03-03 1993-04-21 Chiros Ltd Arylalkanoic acid resolution and microorganisms for use therein
US5912164A (en) * 1993-03-03 1999-06-15 Laboratorios Menarini S.A. Stereoselective hydrolysis of chiral carboxylic acid esters using esterase from ophiostoma or ceratocystis
HUE046680T2 (hu) 2009-09-30 2020-03-30 Codexis Inc Javított Lov-D aciltranszferáz mediált acilezés
CN103937845B (zh) * 2014-04-24 2016-06-22 哈尔滨商业大学 S-(+)-萘普生脂肪酰甘油酯前药的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599944B2 (en) * 1985-12-20 1990-08-02 Wisconsin Alumni Research Foundation Process for preparing (S)-alpha-methylarylacetic acids
AU619249B2 (en) * 1988-02-25 1992-01-23 Istituto Guido Donegani S.P.A. Process for the continuous biotechnological preparation of optical isomer s(+) of 2-(6-methoxy-2-naphthyl) propionic acid
IL91453A0 (en) * 1988-09-02 1990-04-29 Tanabe Seiyaku Co Preparation of optically active 3-phenyl-glycidic acid esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9323547A1 *

Also Published As

Publication number Publication date
NO944336L (no) 1994-11-14
MX9302853A (es) 1993-11-01
FI945353A0 (fi) 1994-11-14
FI945353A7 (fi) 1994-11-14
FI945353L (fi) 1994-11-14
NO944336D0 (no) 1994-11-14
WO1993023547A1 (fr) 1993-11-25

Similar Documents

Publication Publication Date Title
US8372595B2 (en) Method for obtaining a microbial strain for production of sphingoid bases
US6645746B1 (en) Carbonyl reductase, gene thereof and method of using the same
JP2003339391A (ja) エステラーゼ
CA2441267A1 (fr) Reduction stereoselective d'acetophenone substitue
JPWO1998035025A1 (ja) 新規カルボニル還元酵素、およびこれをコードする遺伝子、ならびにこれらの利用方法
KR20020097210A (ko) 아시도보락스 파실리스 ７２ｗ로부터의 니트릴라제에 대한유전자의 단리 및 발현 방법
EP0644940A1 (fr) PROCEDE ENZYMATIQUE POUR LA PRODUCTION D'ACIDE $i(S)-6-METHOXY-ALPHA-METHYLE-2 NAPHTALENACETIQUE
US5457051A (en) Enantioselective hydrolysis of ketoprofen esters by beauveria bassiana and enzymes derived therefrom
RU2333958C2 (ru) Бутинол i эстераза
JP2003502021A (ja) アスペルギルス起源のエポキシドヒドロラーゼ
Kallwass et al. Enzymes for the resolution of α-tertiary-substituted carboxylic acid esters
JP4571936B2 (ja) パントラクトンヒドロラーゼ
US6828129B2 (en) Esterase genes and uses of the same
JP3855329B2 (ja) エステラーゼ遺伝子及びその利用
JPH10210974A (ja) エステラーゼ遺伝子及びその利用
US6407284B1 (en) Method of resolving 2-oxobicyclo [3.1.0] hexane-6-carboxylic acid derivatives
US6472189B1 (en) Esterase gene and its use
AU2946999A (en) Improvements in or relating to fatty acid metabolism
JP2006115729A (ja) 光学活性β−ヒドロキシアミノ酸の晶析方法
JP6088973B2 (ja) 新規アミダーゼ
JPH03210183A (ja) エステルヒドロラーゼ遺伝子の大腸菌内でのクローニング、発現、および配列決定
JPH1132771A (ja) 光学活性グリシド酸エステル及び光学活性グリセリン酸エステルの製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19960417

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960828